Minerva Neurosciences, Inc. (NERV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

3.7600

-0.9700

(-20.51%)

As of 01:14PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Short-term KST

View all chart patterns

Performance Outlook

Previous Close	4.7300
Open	4.3800
Bid	3.6400 x 1800
Ask	3.6700 x 1000
Day's Range	3.6116 - 4.4663
52 Week Range	2.5100 - 17.0400
Volume	326,138
Avg. Volume	680,335

Market Cap	20.079M
Beta (5Y Monthly)	0.91
PE Ratio (TTM)	N/A
EPS (TTM)	-1.1920
Earnings Date	Nov 07, 2022 - Nov 11, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	53.33

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NERV

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Minerva Neurosciences, Inc
Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
Rating
Fair Value
Economic Moat
18 hours agoMorningstar

All

GlobeNewswire
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2022. Roluperidone Update Following the March 2, 2022 Type C Meeting with th
- Top Financial Stocks for August 2022
  Investopedia
- FREYR Battery Reports Second Quarter 2022 Results
  Business Wire
Simply Wall St.
Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
GlobeNewswire
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2022. Roluperidone Update On April 7, 2022, the Company issued a press release pr